Letter to Editor
Authors
Department of Biotechnology and Bioinformatics, School of Life Sciences, JSS Academy of Higher Education and Research, Mysore, Karnataka, India
- Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH,
et al. Immunogenicity and safety of a recombinant
adenovirus type-5-vectored COVID-19 vaccine in healthy
adults aged 18 years or older: A randomised, double-blind,
placebo‑controlled, phase 2 trial. Lancet 2020;396:479‑88.
2. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S,
Belij-Rammerstorfer S, et al. Safety and immunogenicity of the
ChAdO×1 nCoV-19 vaccine against SARS-CoV-2: A preliminary
report of a phase 1/2, single‑blind, randomised controlled trial.
Lancet 2020;396:467‑78.
3. Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JI-P,
et al. Potential rapid diagnostics, vaccine and therapeutics for
2019 novel coronavirus (2019-nCoV): A systematic review.
J Clin Med 2020;9:623.
4. Smith TRF, Patel A, Ramos S, Elwood D, Zhu X, Yan J, et al.
Immunogenicity of a DNA vaccine candidate for COVID-19.
Nat Commun 2020;11:1‑13. - 5. Jamrozik E, Selgelid MJ. COVID-19 human challenge studies:
Ethical issues. Lancet Infect Dis 2020;3099:18‑20. Available
from: http://dx.doi.org/10.1016/S1473‑3099(20)30438‑2. [Last
accessed on 2020 Aug 01].
)